The Global Epigenetics Market is Projected to Reach $1.60 billion

Posted September 13, 2019 by HealthcareNews

The global epigenetics market is projected to reach USD 1.60 billion by 2022 from USD 0.85 billion in 2016, at a CAGR of 13.3%
According to a new market research report "Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) - Global Forecast to 2022", published by MarketsandMarkets™, the market is projected to reach USD 1,605.7 million by 2022 from an estimated USD 854.0 million in 2017, at a CAGR of 13.5% during the forecast period.

Download PDF Brochure:

The major players in the Global Epigenetics Market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (US), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).

The key factors that are driving the growth of this market include the decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer.

Browse and in-depth TOC on "Epigenetics Market"
191 - Tables
37 - Figures
230 – Pages

North America accounted for the largest share of the Epigenetics Market in 2016, followed by Europe. Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the Epigenetics Market in North America.

Major Market Developments
In July 2017, Agilent launched AriaDx Real-Time PCR System

In June 2017, Illumina launched Extended RAS Panel, a NGS kit

In January 2017, Illumina entered into an agreement with Koninklijke Philips (Netherlands) to integrate Ilumina’s sequencing systems with Philips’ IntelliSpace Genomics clinical informatics platform for oncology
Pharmaceutical companies and research laboratories require many such systems. Therefore, significant investments are required for procuring multiple, high-cost genomic instruments. End users such as academic research laboratories find it difficult to afford such systems as they have constricted budgets. High instrument costs, therefore, hinder their wide adoption, which is expected to restrict market growth during the forecast period.

List of Figures (37 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Bottom-Up Approach
Figure 4 Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Global Epigenetics Market, By Product, 2017 vs 2022 (USD Billion)
Figure 7 Global Epigenetics Market, By Application, 2017 vs 2022 (USD Billion)
Figure 8 Global Epigenetics Market, By Technology, 2017 vs 2022 (USD Billion)
Figure 9 Global Epigenetics Market, By End User, 2017 vs 2022 (USD Billion)
Figure 10 Geographic Snapshot: Epigenetics Market

Read more:
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Healthcare News
Phone 18886006441
Business Address USA
Country United States
Categories Medical , News , Research
Tags epigenetics , epigenetics market
Last Updated September 13, 2019